Gerresheimer (ETR:GXI) received a €49.50 ($57.56) target price from research analysts at JPMorgan Chase & Co. in a note issued to investors on Monday. The firm currently has a “sell” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential downside of 17.71% from the company’s current price.

Several other equities analysts have also recently commented on the stock. Deutsche Bank set a €86.00 ($100.00) target price on shares of Gerresheimer and gave the company a “buy” rating in a research note on Tuesday, January 15th. Berenberg Bank set a €81.00 ($94.19) target price on shares of Gerresheimer and gave the company a “buy” rating in a research note on Friday, November 23rd. Hauck & Aufhaeuser set a €55.00 ($63.95) price objective on shares of Gerresheimer and gave the company a “neutral” rating in a research report on Monday, October 15th. Kepler Capital Markets set a €62.00 ($72.09) price objective on shares of Gerresheimer and gave the company a “sell” rating in a research report on Friday, October 12th. Finally, Credit Suisse Group set a €88.00 ($102.33) price objective on shares of Gerresheimer and gave the company a “buy” rating in a research report on Friday, October 12th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of €69.77 ($81.13).

Gerresheimer stock opened at €60.15 ($69.94) on Monday. Gerresheimer has a 52 week low of €59.97 ($69.73) and a 52 week high of €78.25 ($90.99).

About Gerresheimer

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Featured Story: Rule of 72

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.